Le cannabidiol en traitement «anti-addictif» chez les patients alcooliques : l’étude CARAMEL PHRC-N 2018 n°0198 Investigateur principal B. Rolland François Bailly, service d’hépatologie et d’addictologie, Hôpital de la Croix Rousse, Lyon. Le cannabidiol en traitement « anti-addictif » chez les patients alcooliques : l’étude CARAMEL François Bailly Hôpital de la Croix-Rousse, Lyon Le protocole CARAMEL, qui devrait démarrer début 2020, est destiné à étudier l’intérêt du cannabidiol dans la dépendance alcoolique. Le projet d’étude est centré sur les effets du CBD sur le système nerveux central et les neuroprotecteurs et antioxydants, qui ont un impact sur la toxicité de l’alcool au niveau du cerveau et du foie, [...]
Lire la suite'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]
Lire la suitePsychedelic Cuts Cravings, Consumption in Alcohol Use Disorder Pauline Anderson Medscape, May 23, 2019 https://www.medscape.com/viewarticle/913422?src=wnl_tp10n_190711_mscpedit&uac=292598PZ&impID=2023688&faf=1 SAN FRANCISCO — Just two doses of the psychedelic drug psilocybin, taken over a period of 8 weeks, significantly reduced alcohol use and cravings in patients with alcohol use disorder, preliminary findings show. In the first study to use modern clinical trial design to investigate the effects of a hallucinogen in alcohol-dependent patients, investigators at New York University (NYU) School of Medicine in New York City found that use of psilocybin was significantly associated with fewer drinking days and fewer drinks per day, as well fewer cravings. Dr Kelley Clark O'Donnell "Psychedelic [...]
Lire la suiteChapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]
Lire la suiteA phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, LUÍS FERNANDO TÓFOLI, BRUNO DANIEL RASMUSSEN CHAVES, DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (2), pp. 74–83 DOI: 10.1556/2054.01.2017.007 Objective : This report documents the phenomenology of the subjective experiences of 22 patients with substancerelated disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods: Participants underwent a one-to-one semi structured interview exploring the subjective effects of ibogaine. We employed interpretative phenomenological analysis [...]
Lire la suiteCan 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder ? Ben SESSA Journal of Psychedelic Studies, 2017, 1, (1), pp. 1–9 DOI: 10.1556/2054.01.2016.003 Treating people with alcohol use disorder has been an important target area for psychedelic research – both in the first studies of the 1950s and during the Psychedelic Renaissance of the last 10 years. To date, most studies have looked at the classical psychedelic drugs as adjuncts to psychotherapy; with attention paid to the psychospiritual aspect of the experience as a central therapeutic process in effecting abstinence from drinking. Psychotherapy assisted with 3,4,-methylenedioxymethamphetamine (MDMA) has never been explored for treating [...]
Lire la suiteTreating drug dependence with the aid of ibogaine: A qualitative study EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, BRUNO DANIEL RASMUSSEN CHAVES, LUÍS FERNANDO TO´ FOLI and DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (1), pp. 10–19 DOI: 10.1556/2054.01.2016.002 Background : Substance use disorders are important contributors to the global burden of disease, but current treatments are not associated with high rates of recovery. The lack of approved and effective treatments is acutely problematic for psychostimulants like cocaine and crack cocaine. One promising alternative in the treatment of drug dependence in general and psychostimulants in particular [...]
Lire la suiteThe antiaddictive effects of ibogaine : A systematic literature review of human studies Rafael G. DOS SANTOS, José Carlos BOUSO and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 20–28 DOI: 10.1556/2054.01.2016.001 Background and aims : Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Methods : Papers published up to July 2, 2016 were included from PubMed, LILACS, and SciELO databases [...]
Lire la suiteDetoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report CLARE WILKINS, RAFAEL G. DOS SANTOS, JORDI SOLÁ, MARC AIXALÁ, PEP CURA, ESTEFANÍA MORENO, MIGUEL ÁNGEL ALCÁZAR-CÓRCOLES, JAIME E. C. HALLAK and JOSÉ CARLOS BOUSO Journal of Psychedelic Studies, 2017, 1, (1), pp. 29–34 DOI: 10.1556/2054.01.2017.005 Background and aims : Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, [...]
Lire la suiteSubjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning ALAN K. DAVIS, JOSEPH P. BARSUGLIA, MARLEY WINDHAM-HERMAN, MARTA LYNCH and MARTIN POLANCO Journal of Psychedelic Studies, 2017, 1, (2), pp. 65–73 DOI: 10.1556/2054.01.2017.009 Background and aims : Very few studies have reported the effectiveness of ibogaine as a treatment for chronic opioid use. Therefore, this study evaluated the acute subjective effects of ibogaine, outcomes on problematic opioid consumption, and the long-term associations with psychological functioning. Methods : Using online data collection, 88 patients who received ibogaine treatment in Mexico between 2012 and 2015 completed our survey. Results : [...]
Lire la suite